Ocugen (OCGN) Announces Proposed Public Offering of Common Stock

Ocugen, Inc. (Nasdaq: OCGN), a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19, today announced that it has commenced an underwritten public offering of its common stock. In addition, Ocugen expects to grant to the underwriter a 30-day option to purchase up to an additional 15% of shares of the common stock sold in the public offering. All of the securities in the offering are to be sold by Ocugen. The offering is subject to market and other customary closing conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

Ocugen intends to use the net proceeds of the proposed offering for general corporate purposes, capital expenditures, working capital and general and administrative expenses

Cantor Fitzgerald & Co. is acting as the sole book-running manager for the offering.

You May Also Be Interested In

• Cantor Fitzgerald Starts Apnimed Inc. (APMD) at Overweight
• Cantor Fitzgerald Starts Milestone Pharmaceuticals (MIST) at Overweight
• Metaplanet (MTPLF) Reiterated at Overweight by Cantor Fitzgerald